News

Alpha-2b incorporates the company’s Biphasix drug delivery technology and provides a better means of delivering interferon-alpha-2b therapeutically to human papillomavirus (HPV) infected tissues. FDA will take 30 days

Under the agreement, which spans over 18 months, the companies will analyse the genomes of patients to search for sequence variants to gain further insights into drug targets.

The Ramsell Care Continuum is an integrated solution developed specifically for an ADAP program to address the needs of HIV/AIDS patients. The Ramsell Care Continuum features a software

GMI-1070 is a pan-selectin antagonist currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. GMI-1070, which is believed to inhibit selectin

The grant is intended to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. GSK2118436 is an investigational drug that is orally

MM-121 is a fully human monoclonal antibody that targets ErbB3. The Phase 2 study will assess efficacy of MM-121 in combination with paclitaxel as compared to treatment with

The study MODERN [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen] or A4001095 will test the efficacy of Celsentri/Selzentry (maraviroc) versus emtricitabine/tenofovir (Truvada), both

The move in this direction has been made on the back of growing potential in the Brazilian pharma market. Celesio CEO Markus Pinger said Brazil’s healthcare market grows

Other Azelon investors are Lighthouse Capital Partners and Covington Venture Fund. ZT-034, which comprises teriparatide (PTH1-34) is said to provide an alternative for patients at high risk of